Monthly Archives: September 2018

Power Integrations, Inc. v. Fairchild Semiconductor Int., et al.

Posted on September 27, 2018 by Patrick J. Halloran, Ph.D., J.D.

Docket No. 2016-2691, 2017-1875 DYK, CLEVENGER, CHEN July 3, 2018 (updated September 25, 2018) Update: Original opinion modified on Sept. 20, 2018 following a petition for rehearing filed by Power Integrations (PI) but the same decisions were reached (DC claim … Continue reading →

Posted in Claim Construction, Damages, Doctrine of equivalents, Infringement, Royalties | Leave a comment

ParkerVision, Inc. v. Qualcomm Inc. et al.

Posted on September 24, 2018 by Patrick J. Halloran, Ph.D., J.D.

Docket No. 2017-2012, -2013, -2014, 2074 (IPR2015-01828, -01829, -01831) O’MALLEY, REYNA, TARANTO September 13, 2018 Brief summary: Board’s IPR decisions finding certain claims of PV’s patent relating to cellular phones obvious affirmed (e.g., “[a]ny motivation to combine references, whether articulated … Continue reading →

Posted in Inter Parties Review (IPR), IPR, Obviousness | Leave a comment

E.I. DuPont De Nemours & Co. et al. v. Synvina C.V.

Posted on September 19, 2018 by Patrick J. Halloran, Ph.D., J.D.

Docket No. 2017-1977 (IPR2015-01838) LOURIE, O’MALLEY, CHEN September 17, 2018 Brief summary: FC panel reversed the Board IPR decision of nonobviousness, writing that “this case involves a strong case of obviousness based on very close prior art and weak evidence … Continue reading →

Posted in Inter Parties Review (IPR), IPR, Obviousness | Leave a comment

Nobel Biocare Services AG v. Instradent USA, Inc.

Posted on September 17, 2018 by Patrick J. Halloran, Ph.D., J.D.

Docket No. 2017-2259 (IPR2015-01786) PROST, LOURIE, CHEN September 13, 2018 Brief summary: Board IPR decision finding Nobel’s claims relating to dental implants are invalid for anticipation affirmed, based in part on finding that trade show catalog was publicly available under … Continue reading →

Posted in Anticipation (35 USC 102), Inter Parties Review (IPR), IPR | Leave a comment

Orexo AB et al. v. Actavis Elizabeth LLC

Posted on September 14, 2018 by Patrick J. Halloran, Ph.D., J.D.

Docket No. 2017-1333 NEWMAN, HUGHES, STOLL September 10, 2018 Brief summary: DC holding of Orexo’s Orange Book-listed claims related to the opioid dependence drug Zubsolv® invalid for obviousness reversed and remanded. Summary: Orexo appealed DC holding of claims 1, 3-6 … Continue reading →

Posted in Generics / ANDA, Obviousness | Leave a comment

Acorda Therapeutics, Inc. / Alkermes Pharma v. Roxane / Mylan / Teva (“Defendants”)

Posted on September 13, 2018 by Patrick J. Halloran, Ph.D., J.D.

Docket No. 2017-2078, -2134 NEWMAN (D), DYK, TARANTO September 10, 2018 Brief summary: DC invalidation of four Orange Book (“OB”) patents relating to Acorda’s Ampyra® product for obviousness affirmed. Summary: Acorda appealed DC finding that the claims of its four … Continue reading →

Posted in Generics / ANDA, Obviousness, Obviousness-Teaching Away | Leave a comment

Regents of The University of California, University of Vienna, Emmanuelle Charpentier (“UC”) v. Broad Institute, Inc., Mass. Inst. Tech., Fellows of Harvard College (“Broad”)

Posted on September 11, 2018 by Patrick J. Halloran, Ph.D., J.D.

Docket No. 2017-1907 PROST, SCHALL, MOORE September 10, 2018 Brief summary: FC panel affirmed the Board’s judgment of no interference-in-fact between UC’s and Broad’s claims, also stating that this “is not a ruling on the validity of either set of … Continue reading →

Posted in Interference, Obviousness | Leave a comment

Worlds Inc. v. Bungie Inc.

Posted on September 10, 2018 by Patrick J. Halloran, Ph.D., J.D.

Docket No. 2017-1481, -1546, -1583 (IPR2015-01264, -01319, -01321) PROST, O’MALLEY, TARANTO September 7, 2018 Brief summary: Board’s IPR invalidation decisions vacated and remanded (“the Board should first address whether Worlds is estopped from arguing the real-party-in-interest issue” and “then reevaluate … Continue reading →

Posted in Collateral estoppel, Inter Parties Review (IPR), IPR, Issue Preclusion | Leave a comment

Supernus Pharmaceuticals, Inc. v. TWi Pharmaceuticals, Inc. et al.

Posted on September 7, 2018 by Patrick J. Halloran, Ph.D., J.D.

Docket No. 2017-2513 O’MALLEY, CLEVENGER, STOLL September 6, 2018 Non-precedential Brief summary: DC finding that TWi’s ANDA to Supernus’s Oxtellar XR® would infringe the asserted OB-listed patents and that the claims are not invalid affirmed. Summary: TWi appealed DC holding … Continue reading →

Posted in Claim Construction, Generics / ANDA, Infringement, Prosecution History Estoppel | Leave a comment

Align Technology, Inc. v. ClearCorrect Operating, LLC

Posted on September 5, 2018 by Patrick J. Halloran, Ph.D., J.D.

Docket No. 2017-2106 PROST, TARANTO, CHEN August 22, 2018 Non-precedential Brief summary: FC panel therefore vacated and remanded the Board’s obviousness decision, but affirmed the Board’s consideration of secondary considerations and claim construction. Summary: Align appealed Board IPR decision finding … Continue reading →

Posted in Claim Construction, Inter Parties Review (IPR), IPR, Obviousness | Leave a comment